What is the recommended evaluation and management for an extraluminal bladder mass?

Evaluation and Management of Extraluminal Bladder Mass

An extraluminal bladder mass requires immediate cross-sectional imaging with CT or MRI followed by cystoscopy with transurethral resection and bimanual examination under anesthesia to establish tissue diagnosis and assess for extravesical extension of bladder cancer.

Initial Diagnostic Approach

The presence of an extraluminal bladder mass is concerning for locally advanced bladder cancer with extravesical extension (≥T3 disease) or, less commonly, a rare exophytic tumor or inflammatory process. The evaluation must proceed systematically:

Imaging Evaluation

• CT or MRI of abdomen/pelvis is essential for assessing extravesical invasion, though both modalities cannot reliably detect T3a disease (microscopic perivesical fat invasion) and may be confounded by post-surgical inflammation 1
• MRI with VI-RADS scoring offers superior soft tissue contrast and can better differentiate tumor extent, particularly for detecting muscle invasion 2
• CT chest should be performed concurrently to evaluate for metastatic disease 1
• Look specifically for:
  • Hydronephrosis (independent predictor of advanced stage and extravesical disease) 1
  • Enlarged lymph nodes (>8mm pelvic, >1cm abdominal) 1
  • Adjacent organ invasion 1

Cystoscopic Evaluation and Tissue Diagnosis

Cystoscopy with TURBT and bimanual examination under anesthesia is mandatory to:

• Obtain tissue for histologic diagnosis 1
• Document tumor size, location, and appearance 1
• Assess for intraluminal component 3
• Perform bimanual examination to detect palpable masses and assess fixation 1

Critical pitfall: Extraluminal masses may have minimal or necrotic intraluminal components, making biopsy challenging 4. If initial biopsy is non-diagnostic but imaging is suspicious, repeat resection or open biopsy may be necessary.

Additional Workup

• Complete blood count, creatinine, creatinine clearance 1
• Alkaline phosphatase (if elevated, obtain bone scan) 5
• Urine cytology 3
• Upper tract imaging (CT urogram preferred) to exclude synchronous upper tract disease 3

Management Based on Findings

If Muscle-Invasive Bladder Cancer (T2-T4a) is Confirmed

Radical cystectomy with pelvic lymph node dissection preceded by neoadjuvant cisplatin-based chemotherapy is the standard treatment for patients fit for surgery 1, 6.

• Neoadjuvant chemotherapy improves survival and should be strongly considered in fit patients 1, 6
• For T3 disease with extravesical extension, radical cystectomy remains the primary treatment 7
• Bladder preservation with trimodality therapy (maximal TURBT + concurrent chemoradiation) is an alternative only in highly selected patients without carcinoma in situ and after complete resection 1, 6

If T4b Disease (Fixed Mass or Adjacent Organ Invasion) or Node-Positive

Platinum-based combination chemotherapy is the primary treatment 5, 8:

• Gemcitabine/cisplatin or MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) 5
• Cystectomy may be considered after response to chemotherapy in selected cases 7
• For cisplatin-ineligible patients with PD-L1 positive tumors, immunotherapy is an option 6

If Rare Histology or Benign Process

Extraluminal bladder masses can rarely represent:

• Inflammatory myofibroblastic tumor: Requires complete surgical excision 9
• Exophytic urothelial carcinoma: May present without hematuria; partial cystectomy possible in selected cases 4
• Endometriosis: Has characteristic MRI features with hemorrhagic foci 10
• Inflammatory pseudotumor: May have extravesical component requiring resection 10

Pathologic diagnosis is essential as imaging cannot reliably distinguish these entities 11, 10.

Key Clinical Pitfalls

1. Do not delay cystoscopy and tissue diagnosis even if imaging suggests extravesical disease—histologic confirmation is mandatory before initiating systemic therapy
2. Bimanual examination under anesthesia is critical but has significant discordance with final pathologic staging (31% understaging, 11% overstaging) 2
3. Extraluminal growth without gross hematuria can delay diagnosis—maintain high suspicion in high-risk patients 4
4. Post-TURBT inflammation can mimic extravesical extension on imaging—ideally perform CT/MRI before resection if sessile or high-grade tumor suspected 1, 5